Topics
Glioblastoma | Treatment | Clinical trials | Aglatimagene besadenovec
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Aglatimagene besadenovec
Wen PY, Manzanera A, Duault C, Gonzalez-Kozlova E, Lopez L,
Grossman SA, Ye X, Fisher J, Lee I, Walbert T, Snyder J, Brem S,
Desai A, Bagley SJ, Kakani C, Strowd R, Tatter S, Laxton A, Lesser
G, Amankulor N, Lieberman F, Drappatz J, Mantica M, Triggs D,
Haymaker C, Wistuba II, Al-Atrash G, Mendoza Perez J, Futreal A,
Little LD, Islam MDH, Duose D, Jiang P, Reuben A, Lawler SE,
Pichavant M, Gentles A, Bendall S, Kong A, Camacho C, Del Valle D,
Kim-Schulze S, Gnjatic S, Sharon E, Nowicki MO, Peruzzi P, Lane D,
Aguilar-Cordova E, Aguilar LK, Nichols G, Dwyer J, Tak PP, Maecker
H, Barone F, Chiocca EA.
A
multi-institutional phase 1 clinical trial exploring upfront
multimodal standard of care and combined immunotherapies for newly
diagnosed glioblastoma.
Neuro
Oncol. 2025 Mar 22:noaf079. doi:
10.1093/neuonc/noaf079. PMID:
40120123. Interventional study˰
ˍ